Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures. The company also develops preclinical pipeline programs, such as Kv7 Program for pain epilepsy; and Anxiolytic for the treatment of generalized anxiety. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
IPO Year: 2021
Exchange: NASDAQ
Website: eliemtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/7/2021 | $32.00 | Buy | Guggenheim |
| 9/7/2021 | $35.00 | Buy | Stifel |
| 9/7/2021 | $33.00 | Outperform | SVB Leerink |
8-K - Climb Bio, Inc. (0001768446) (Filer)
8-K - Eliem Therapeutics, Inc. (0001768446) (Filer)
8-K - Eliem Therapeutics, Inc. (0001768446) (Filer)
8-K - Eliem Therapeutics, Inc. (0001768446) (Filer)
10-Q - Eliem Therapeutics, Inc. (0001768446) (Filer)
EFFECT - Eliem Therapeutics, Inc. (0001768446) (Filer)
424B3 - Eliem Therapeutics, Inc. (0001768446) (Filer)
S-3 - Eliem Therapeutics, Inc. (0001768446) (Filer)
D - Eliem Therapeutics, Inc. (0001768446) (Filer)
D - Eliem Therapeutics, Inc. (0001768446) (Filer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
Guggenheim initiated coverage of Eliem Therapeutics with a rating of Buy and set a new price target of $32.00
Stifel initiated coverage of Eliem Therapeutics with a rating of Buy and set a new price target of $35.00
SVB Leerink initiated coverage of Eliem Therapeutics with a rating of Outperform and set a new price target of $33.00
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM) ("Eliem" or the "Company"), today reported financial results for the quarter ended June 30, 2024 and provided a business
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy Post-close cash and cash equivalents of $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for TNT119 Announces the appointments of Dr. Aoife Brennan as President, Chief Executive Officer and Director, and Dr. Jan Hillson as Senior Clinical Advisor; Dr. Stephen Thomas, former Tenet CEO, appointed to Eliem's Board of Directors SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2024 (GLOBE NEWSWIRE) -- Eliem Ther
Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123 Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment Implementing corporate reorganization to extend cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM) ("Eliem" or the "Company"), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a strategic business update and an
SEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced the strengthening of its executive team with the appointment of Susan Franks, MS as Eliem's Senior Vice President and Head of Regulatory Affairs. Ms. Franks brings with her over 30 years of global regulatory affairs and project management experience working at multiple pharmaceutical companies with an emphasis on pain and CNS
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
3 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective October 3rd WELLESLEY, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today that it will change its corporate name to Climb Bio, Inc. The new name and corporate brand reflect the Company's new mission to develop a pipeline focused on immune-mediated diseases, following its acquisition of Tenet Medicines, Inc. In conjunction with the corporate name change, the Company will begin trading under the new ticker symbol "CLYM" on the Nasdaq Global Mar
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024. Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Format: 1x1 meetings About Eliem Therapeutics, Inc.Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocyto
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development. "I am delighted to announce the addition of Brett and Nishi to our executive team," said Dr. Aoife Brennan, CEO of Eliem Therapeutics. "Since completing the Tenet Medicines acquisition, we have worked diligently to build a best-in-class management team as we transition Eliem into a leading bio
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM) ("Eliem" or the "Company"), today reported financial results for the quarter ended June 30, 2024 and provided a business
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock indexes, effective today. "We are pleased to have earned inclusion in the Russell indexes, among the most widely used benchmarks for small-cap stocks," said Dr. Aoife Brennan, CEO of Eliem Therapeutics. "This is an important milestone for Eliem as we continue to build momentum and develop our world-class science and innovation aimed at harnessing the extraordinary potential of TNT119, a potent, CD19-ta
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy Post-close cash and cash equivalents of $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for TNT119 Announces the appointments of Dr. Aoife Brennan as President, Chief Executive Officer and Director, and Dr. Jan Hillson as Senior Clinical Advisor; Dr. Stephen Thomas, former Tenet CEO, appointed to Eliem's Board of Directors SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2024 (GLOBE NEWSWIRE) -- Eliem Ther
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Companies to host webcast today, April 11, 2024 at 8:30 a.m. EDT SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM) ("Eliem") and Tene
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in the process. As part of this process, Eliem will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other trans
Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, United Kingdom, May 11, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2023
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022. "We are excited to advance
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022. "We are excited to advance
Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported
Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended June 30, 2022. "We continue to advance our pipeline targeting neuronal excitability disorders," said Bob Azelby, pres
SC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13G/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13G - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13G - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
SC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)